Clinical Laboratory, China-Japan Friendship Hospital, No. 2 Yinghua East Street, Chaoyang District, Beijing, 100029, China.
BioChain (Beijing) Science and Technology Inc., No. 18 Hongda South Road, BDA, Beijing, 100176, China.
Clin Epigenetics. 2024 Jan 2;16(1):1. doi: 10.1186/s13148-023-01620-8.
The objective of this study was to examine and analyze differential methylation profiles in order to investigate the influence of hyper-methioninemia (HM) on the development of diabetic nephropathy (DN). Male Wistar rats, aged eight weeks and weighing 250-300 g, were randomly assigned into four groups: a control group (Healthy, n = 8), streptozocin-induced rats (STZ group, n = 8), HM + STZ group (n = 8), and the Tangshen Formula (TSF) treatment group (TSF group, n = 8). Blood glucose levels and other metabolic indicators were monitored before treatment and at four-week intervals until 12 weeks. Total DNA was extracted from the aforementioned groups, and DNA methylation landscapes were analyzed via reduced representative bisulfite sequencing.
Both the STZ group and HM + STZ group exhibited increased blood glucose levels and urinary albumin/creatinine ratios in comparison with the control group. Notably, the HM + STZ group exhibited a markedly elevated urinary albumin/creatinine ratio (411.90 ± 88.86 mg/g) compared to the STZ group (238.41 ± 62.52 mg/g). TSF-treated rats demonstrated substantial reductions in both blood glucose levels and urinary albumin/creatinine ratios in comparison with the HM + STZ group. In-depth analysis of DNA methylation profiles revealed 797 genes with potential therapeutic effects related to TSF, among which approximately 2.3% had been previously reported as homologous genes.
While HM exacerbates DN through altered methylation patterns at specific CpG sites, TSF holds promise as a viable treatment for DN by restoring abnormal methylation levels. The identification of specific genes provides valuable insights into the underlying mechanisms of DN pathogenesis and offers potential therapeutic targets for further investigation.
本研究旨在检测和分析差异甲基化谱,以探讨高蛋氨酸血症(HM)对糖尿病肾病(DN)发展的影响。8 周龄、体重 250-300g 的雄性 Wistar 大鼠随机分为 4 组:对照组(健康组,n=8)、链脲佐菌素诱导大鼠(STZ 组,n=8)、HM+STZ 组(n=8)和糖肾方(TSF)治疗组(TSF 组,n=8)。治疗前和 4 周间隔监测血糖水平和其他代谢指标,直至 12 周。从上述各组提取总 DNA,通过简化代表性亚硫酸氢盐测序分析 DNA 甲基化图谱。
与对照组相比,STZ 组和 HM+STZ 组的血糖水平和尿白蛋白/肌酐比值均升高。值得注意的是,HM+STZ 组的尿白蛋白/肌酐比值(411.90±88.86mg/g)明显高于 STZ 组(238.41±62.52mg/g)。与 HM+STZ 组相比,TSF 治疗组的血糖水平和尿白蛋白/肌酐比值均显著降低。对 DNA 甲基化图谱的深入分析显示,有 797 个与 TSF 相关的具有潜在治疗作用的基因,其中约 2.3%的基因以前被报道为同源基因。
HM 通过改变特定 CpG 位点的甲基化模式加重 DN,而 TSF 通过恢复异常甲基化水平有望成为 DN 的有效治疗方法。特定基因的鉴定为 DN 发病机制的潜在机制提供了有价值的见解,并为进一步研究提供了潜在的治疗靶点。